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Introduction
Survival in a terrestrial environment necessitates the prevention of 
water and electrolyte loss through the body surface to minimize 
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Keratinocyte differentiation is essential for skin development 
and the formation of the skin permeability barrier. This process 
involves an orchestrated remodeling of lipids. The cleavage of 
precursor lipids from lamellar bodies by β-glucocerebrosidase, 
sphingomyelinase, phospholipases and sterol sulfatase 
generates ceramides, non-esterified fatty acids and 
cholesterol for the lipid-containing extracellular matrix, the 
lamellar membranes in the stratum corneum. The importance 
of triacylglycerol (TAG) hydrolysis for the formation of a 
functional permeability barrier was only recently appreciated. 
Mice with defects in TAG synthesis (acyl-CoA:diacylglycerol 
acyltransferase-2-knock-out) or TAG catabolism (comparative 
gene identification-58, -CGi-58-knock-out) develop severe 
permeability barrier defects and die soon after birth because 
of desiccation. in humans, mutations in the CGi-58 gene also 
cause (non-lethal) neutral lipid storage disease with ichthyosis. 
As a result of defective TAG synthesis or catabolism, humans 
and mice lack ω-(O)-acylceramides, which are essential 
lipid precursors for the formation of the corneocyte lipid 
envelope. This structure plays an important role in linking 
the lipid-enriched lamellar membranes to highly cross-linked 
corneocyte proteins. This review focuses on the current 
knowledge of biochemical mechanisms that are essential for 
epidermal neutral lipid metabolism and the formation of a 
functional skin permeability barrier.
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desiccation. In mammals, the epidermal permeability barrier in 
the cornified layer of the skin (stratum corneum) provides this 
function. The barrier is built during keratinization and consists 
of terminally differentiated keratinocytes (corneocytes), which 
are connected by protein cross-linking. These large aggregates are 
embedded in a lipid-containing extracellular matrix that mediates 
permeability barrier function.1-5 This prevents the excessive loss 
of body fluids but in addition also provides an effective barrier 
against environmental xenobiotics and host infections by patho-
gens. The most common lipids found in the extracellular matrix 
of the stratum corneum are ceramides, cholesterol and non-ester-
ified fatty acids (FAs).6-8 They originate from enzymatic conver-
sion of glucosylceramides, sphingomyelins, glycerophospholipids 
and cholesterol sulfate, which are secreted by lamellar bodies 
from keratinocytes at the stratum granulosum/stratum corneum 
interphase.9-13 Triacylglycerols (TAGs) are a minor lipid species of 
lamellar bodies10,11 and as a result epidermal TAG metabolism did 
not obtain much attention in the past. Recent discoveries, how-
ever, demonstrated that dysfunction and deficiencies of enzymes 
and activators of TAG synthesis and catabolism cause major skin 
defects in mice and humans. These findings summarized in this 
review suggest a crucial role of neutral lipid metabolism in the 
generation of a functional permeability barrier in the skin.
Neutral Lipid Storage Disease, a Phenotypically 
Heterogeneous Disorder
The first indication that neutral lipid metabolism may be linked 
to skin function was obtained in 1966 when Rozenszajn et al.14 
reported on two sisters suffering from neutral lipid storage dis-
ease (NLSD) and severe ichthyosis. Later, Dorfman et al.15 and 
Chanarin et al.16 presented additional cases of NLSD patients 
with ichthyosis and the condition was subsequently termed 
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human genome, the CGI-58 gene is located on chromosome 
3 and consists of 7 exons spanning a region of about 31.8 kb. 
Translation of the 1,050 bp mRNA results in a protein composed 
of 349 amino acids with a molecular mass of approximately 39 
kDa. The human protein shares an amino acid homology of 94% 
with its murine orthologue. The highest expression of CGI-58 is 
observed in mature adipocytes and testes, but lower levels are also 
detected in liver, skeletal and cardiac muscle, skin and brain.34,46
Despite the causal relationship between mutations in CGI-58 
and the development of DCS, the biochemical function of the 
protein remained elusive for a long time. CGI-58 belongs to the 
esterase/thioesterase/lipase subfamily of proteins, structurally 
defined by the presence of an α/β hydrolase fold. Accordingly, 
CGI-58 is also annotated as α/β hydrolase domain containing 
5(ABHD5). Unlike all other members of this protein family, 
however, the putative active serine within the canonical esterase/
lipase GXSXG sequence motif of the catalytic triad is replaced 
by an asparagine residue in the corresponding sequence region 
of CGI-58 (amino acid residue 153 of the human protein).29 As a 
result, CGI-58 does not exhibit lipase/esterase activity in in vitro 
studies.34,47
An important function of CGI-58 was discovered in 2006.   
In this study Zechner and colleagues34 demonstrated that effi-
cient hydrolysis of TAGs by adipose triglyceride lipase (ATGL) 
depends on the presence of CGI-58. ATGL is an essential 
enzyme for the hydrolytic degradation of TAGs, a process com-
monly named lipolysis. The complete catabolism of TAGs to 
FAs and glycerol requires the hydrolytic activities of three spe-
cific lipases:48-51 Adipose triglyceride lipase (ATGL; also termed 
desnutrin, patatin-like phospholipase domain containing 
2,PNPLA2, or transport secretion protein-2.2,TTS-2.2) exhib-
its high substrate specificity for TAGs and catalyzes the initial 
step in lipolysis by removing the first FA from TAG molecules 
thereby generating diacylglycerols (DAGs). Hormone-sensitive 
lipase (HSL) is the major lipase in DAG hydrolysis, leading to the 
formation of monoacylglycerols (MAGs) and FAs. In the final 
step of lipolysis, monoglyceride lipase (MGL) hydrolyzes MAGs 
to glycerol and FAs. CGI-58 interacts with ATGL, thereby stim-
ulating its enzymatic activity up to 20-fold.34 Mutant variants 
of CGI-58, harboring amino acid substitutions, which lead to 
DCS, completely lose their ability to activate ATGL-mediated 
lipolysis.34,52 Conversely, expression of functional CGI-58 in 
DCS fibroblasts restored TAG hydrolysis and reversed the lipid 
storage phenotype in these cells.34 Thus, CGI-58 appears to be an 
essential regulatory factor for efficient cellular TAG catabolism. 
Defective TAG catabolism also provided a plausible biochemical 
explanation for the multi-systemic TAG accumulation in patients 
lacking functional CGI-58.
Mutations in the ATGL Gene Cause NLSD  
with Myopathy but not Ichthyosis
The functional link between CGI-58 and ATGL suggested that 
in a subpopulation of patients NLSD may be actually caused 
by mutations in the ATGL gene (PNPLA2). Indeed, in 2007   
Fischer et al.53 published several mutations in PNPLA2 showing 
autosomal recessive disorder characterized by excessive deposi-
tion of neutral lipids in multiple organs of the body. The very 
first case report about a patient suffering from NLSD was pub-
lished in the early 1950s. In this report,17 Jordans documented 
the presence of large neutral lipid-containing vacuoles in white 
blood cells (“Jordans’ anomaly”) of two brothers. Both individu-
als also suffered from a rapidly progressing skeletal and cardiac 
myopathy, as well as liver steatosis. In contrast to the patients 
reported by Dorfman et al.15 and Chanarin et al.16 these broth-
ers showed no signs of ichthyosis or other skin defects suggest-
ing genetic and clinical heterogeneity among NLSD patients. To 
date, a total of more than 50 NLSD cases have been reported. 
Besides the consistently occurring multi-systemic accumulation 
of TAGs in these patients, the more inconsistent clinical mani-
festations of the disorder include ichthyosis, skeletal and cardiac 
myopathy, liver steatosis with hepatosplenomegaly, neurosensory 
hearing loss, ataxia, horizontal nystagmus, mental retardation or 
developmental disorders, such as short stature, microcephalus 
and ear abnormalities.14-19
Early biochemical studies with cultured skin fibroblasts 
derived from DCS patients demonstrated that the total cel-
lular TAG content was up to 20-fold higher than in controls, 
even when cells were cultivated in lipid-deficient media.20 
Biochemical experiments revealed normal FA uptake, transport 
and β-oxidation. With regard to TAG and phospholipid metabo-
lism, two biochemical defects were identified: Willliams et al.21, 
Salvayre, Douste-Blazy and colleagues22-26 concluded from their 
studies that TAG accumulation in NLSD fibroblasts is due to 
a functional deficiency of a TAG lipase. In contrast, Igal and 
Coleman27,28 found that TAG hydrolysis was normal in NLSD 
fibroblasts but instead demonstrated that acylglycerol recy-
cling to phospholipids was defective and caused increased DAG 
reesterification and TAG formation. However, the actual gene(s) 
and protein(s) causing NLSD remained unidentified.
Mutations in the Gene Encoding  
“Comparative Gene Identification-58”  
Cause NLSD with Ichthyosis
Important progress was made in 2001, when the group of Fischer 
and colleagues29 found several causative mutations in the gene 
coding for “comparative gene identification-58” (CGI-58) in 
patients with DCS. Currently, more than two dozen different 
mutations in the human CGI-58 gene are known including mis-
sense mutations, nonsense mutations, splice site mutations at 
exon-intron boundaries and insertion/deletion mutations.29-42 
Importantly, all known NLSD patients, who are affected by 
mutations in the CGI-58 gene, suffer from ichthyosis. The ich-
thyosiform phenotype of DCS most closely resembles non-bul-
lous congenital ichthyosiform erythroderma and is characterized 
by a pronounced defect in the permeability barrier function of 
the skin leading to an increased transepidermal water loss.43,44
As the name implies, CGI-58 was originally identified in a 
comparative-gene-identification approach, where the human pro-
teome and the proteome of the nematode Caenorhabditis elegans 
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barrier dysfunction. This study demonstrated reduced TAG 
hydrolase activity in association with increased TAG accumu-
lation and the absence of measurable concentrations of ω-(O)-
acylceramide (acylceramides) species in the CGI-58-deficient 
epidermis.62 The defect could be partially restored by the addi-
tion of purified CGI-58, but not by ATGL. These observations 
suggest that CGI-58 activates a TAG-lipase distinct from ATGL, 
which is required for the provision of FAs for the esterification 
of ω-OH-ceramides to generate acylceramides. Acylceramides 
are critical for the covalent binding of ω-OH-ceramides to struc-
tural proteins of corneocytes (involucrin, envoplakin and peripla-
kin).63-65 This layer of protein-bound ω-OH-ceramides is referred 
to as corneocyte lipid envelope (CLE) and provides an interface 
between the cross-linked corneocyte proteins and the lipid-con-
taining extracellular matrix. The generation of acylceramides 
and their involvement in the development of a functional CLE is 
summarized in Figure 1. Acylceramides are formed from cerami-
des by amide bonding of very-long chain FAs to sphinganine, 
that ATGL dysfunction causes NLSD. To date, 
14 patients with 9 different mutations have 
been reported in references 53–60. All patients 
exhibit the classical symptoms of multi-systemic 
TAG accumulation. Surprisingly, however, 
NLSD patients with mutations in the ATGL 
gene do not develop ichthyosis. Instead, these 
patients, compared to those with mutated CGI-
58, suffer from more severe forms of skeletal and 
cardiac myopathy. The cardiac myopathy can 
be lethal and requires heart transplantation in 
many cases.58 In consideration of the phenotyp-
ical differences due to distinct genetic defects, 
Fischer et al.53 suggested the name “NLSD 
with myopathy” (NLSDM) for the subgroup 
of patients lacking normal ATGL function and 
“NLSD with ichthyosis” (NLSDI) for those 
patients, who are affected by CGI-58 mutations 
(previously termed DCS).
The clinical symptoms of NLSDM resemble 
in many ways the phenotype of ATGL-deficient 
mice, i.e., excessive accumulation of TAG 
in multiple tissues and cell types, including 
heart, skeletal muscle, liver and lymphocytes.61 
Notably, ATGL-deficient mice just like humans 
suffering from NLSDM also do not display 
ichthyosis or other forms of skin defects. This 
argues against the involvement of ATGL in the 
development of ichthyosis and provides strong 
evidence for an ATGL-independent function of 
CGI-58 in epidermal lipid metabolism.
The ATGL-Independent Function  
of CGI-58 in the Skin:  
Role of Epidermal TAG Hydrolysis
An ATGL-independent function of CGI-58 
was evident, when Radner et al.62 reported on 
the phenotype of mice lacking CGI-58. Similar as observed in 
patients suffering from NLSDI, newborn CGI-58-deficient mice 
suffer from an ichthyosiform skin defect. In contrast to NLSDI 
patients, however, the defect is much more severe leading to rapid 
desiccation and premature death within a few hours after birth. 
The reason for this phenotypical difference between CGI-58-
defective humans and mice is currently unknown. A plausible 
explanation could be that humans have a more advantageous 
ratio of body volume to skin surface, impeding rapid dehydra-
tion. Indirect support for this speculation came from a recently 
published NLSDI case report on a patient with strong seasonal 
variation of disease activity.39 Ichthyosiform skin lesions in this 
subject recurred every year with beginning of summer and mostly 
disappeared with lower air temperatures in autumn and winter 
indicating more pronounced severity of disease symptoms with 
higher ambient temperatures.
CGI-58 knockout mice also provided a suitable model to 
address questions regarding the biochemical defects leading to 
Figure 1. Schema depicting the role of epidermal triacylglycerol (TAG) metabolism in skin 
permeability barrier development. Acyl-CoA:diacylglycerol acyltransferase-2 (DGAT-2) 
transfers an activated fatty acid (FA-CoA) onto diacylglycerol (DAG) to generate TAG. 
These TAGs are hydrolyzed by a lipase, co-activated by comparative gene identification-58 
(CGi-58). TAG-derived FAs are then activated and transferred by an unknown ω-(O)-
acyltransferase (ω-O-AT?) onto ω-OH-(glucosyl)ceramides (ω-OH-(Glc)Cer). Acylceramides 
(acylCer) are glucosylated by uridine diphosphate glucose:ceramide glucosyltransferase 
(glucosylceramide synthase, GlcCerS). Generated acylglucosylceramides (acylGlcCer) 
are then covalently bound to proteins of the cornified envelope by a transesterification 
reaction (transglutaminase 1, TGM1), deglucosylated (β-glucocerebrosidase-GlcCer’ase) 
and hydrolyzed (ceramidase, Cer’ase). TAG-derived FAs may also act as ligands for nuclear 
hormone receptors, activating transcriptional regulators involved in epidermal differentia-
tion. Excessive epidermal TAG accumulation (as indicated by ↑) may lead to lamellar/non-
lamellar phase separation and permeability barrier dysfunction. Defects in protein function 
(as indicated by flashes) result in ichthyosiform phenotypes.80  Dermato-Endocrinology  volume 3 issue 2
showed a correction of the epidermal structural and functional 
defects.81 A similar transplantation experiment with CGI-58-
deficient mice failed to correct the skin phenotype arguing for a 
skin autonomous pathology.62 Further studies are required to elu-
cidate this interesting difference between the two mouse models. 
Nevertheless, the phenotypes of CGI-58- and DGAT-2-deficient 
mice suggest that in the epidermis FAs have to cycle through 
esterification (TAG synthesis) and re-hydrolysis (TAG degra-
dation by lipases) in order to be available for ω-OH-ceramide 
esterification (Fig. 1).
The ATGL-Independent Function  
of CGI-58 in the Skin: CGI-58 is an  
Acyl-CoA:Lysophosphatidic Acid Acyltransferase
In 2008, Gosh et al.82 reported that CGI-58 exhibits enzyme activ-
ity as an acyl-CoA-dependent lysophosphatidic acid acyltrans-
ferase (LPAAT) generating phosphatidic acid. This activity was 
later confirmed by several other groups.83,84 Phosphatidic acid is a 
key metabolite in the synthesis pathway of both TAGs and glyc-
erophospholipids85,86 and it is therefore conceivable that the CGI-
58-associated LPAAT activity relates to the skin phenotype in 
NLSDI patients and mice with CGI-58 deficiency. Additionally, 
this activity coheres with previous studies by Igal and Coleman27,28 
identifying a defect in the remodeling of TAGs to glycerophos-
pholipids in skin fibroblasts of patients affected by NLSDI   
(see above). To assess whether CGI-58 affects epidermal phos-
pholipid metabolism, Radner et al.62 analyzed LPAAT activity 
and phospholipid composition of normal and CGI-58-deficient 
epidermal explants. In keratinocytes, phospholipids are usu-
ally secreted by lamellar bodies and subsequently hydrolyzed 
by secretory phospholipase A2 activity in the cornified layer.74,75 
Consequently, a lack of phospholipids in the epidermis would 
deplete the extracellular, non-esterified FA pool and impair stra-
tum corneum acidification.87,88 However, CGI-58-deficient mice 
exhibited normal LPAAT activity in skin lysates,62 normal epi-
dermal phospholipid composition,62 and normal acidification of 
the stratum corneum (unpublished observation). These findings 
argue against a major role of CGI-58 in epidermal phospholipid 
metabolism.
Additionally, it is unlikely that the LPAAT activity of CGI-
58 contributes to the net synthesis of TAG in keratinocytes 
because CGI-58-deficiency in humans and mice causes TAG 
accumulation.39,62 This is in contrast to the clinical appear-
ance of patients lacking classical LPAAT enzymes such as 
acyl-CoA:acyglycerol acyltransferase (AGPAT). All of these 
patients suffer from the severe lack of TAGs and lipodystrophy. 
Moreover, mutant proteins of CGI-58 as present in patients 
with NLSDI retain full LPAAT activity in vitro.82 However, 
it is conceivable that the acyltransferase activity of CGI-58 is 
confined to specific cellular compartments (e.g., lipid droplets 
or lamellar bodies) and/or substrates. For example, it may be 
relevant for the production of signaling lipids (e.g. phospha-
tidic acid) that affect keratinocyte differentiation or acyla-
tion of alternative lipid substrates, such as ω-OH-(glucosyl)
ceramides, to generate acyl(glucosyl)ceramides. Although such 
subsequent ω-hydroxylation of these FAs, and esterification of 
the ω-OH group, mostly by linoleic acid. Wertz and Downing66 
have demonstrated in porcine epidermis that the majority of lin-
oleic acid for acylceramide synthesis originates from phospholip-
ids and TAGs. In CGI-58-deficient mice this transfer apparently 
does not occur, leading to the accumulation of ω-OH-ceramides 
and the absence of acylceramides and its secondary products, like 
protein-bound ω-OH-ceramides (Fig. 1).
Importantly, these results conform to observations in the epi-
dermis of NLSDI patients. In humans CGI-58 co-localizes in the 
stratum granulosum with lamellar bodies.67 Lamellar body con-
tents are secreted from keratinocytes into stratum corneum inter-
stices and further metabolized by co-secreted enzymes, including 
TAG hydrolase(s),68 ß-glucocerebrosidase,69-71 sphingomyelin-
ase,72,73 and phospholipase(s).74,75 These enzymes are essential 
for the generation of the lipid constituents of the epidermal bar-
rier.76,77 CGI-58 deficiency in human epidermis results in abnor-
mal lamellar bodies in the granular layer containing neutral lipid 
micro-inclusions that are co-secreted with lamellar contents.30,78 
As a consequence, the excessive incorporation of non-polar lip-
ids into lamellar membranes forms a non-lamellar phase, which 
markedly impairs permeability barrier function (Fig. 1).44 Taken 
together, human CGI-58-deficient epidermis lacks an essential 
TAG hydrolase activity to catabolize lamellar TAGs. Just as in 
CGI-58-deficient mice, the absence of this lipase activity causes a 
lack of acylceramides and protein-bound ω-OH-ceramides in the 
epidermis of NLSDI patients79 arguing for a defective FA transfer 
from TAG (or phospholipids) to ω-OH-ceramides.
Using the ORESTES (open reading frame ESTs) method, 
an excellent study investigating human genes involved in epider-
mal differentiation and barrier function, revealed a list of sev-
eral potential candidates for the postulated unknown epidermal 
TAG lipase.80 The authors identified in the human genome many 
potential lipase genes including members of the lipase-like family 
(LIPK, LIPM and LIPN), the PNPLA family (PNPLA1), the fam-
ily of esterases/carboxyl esterases (CES3) and the ABHD family 
(ABHD9). Whether any of these genes encode lipases involved 
in TAG hydrolysis in a CGI-58-dependent manner remains to 
be explored. The classical enzymes of lipolysis (ATGL, HSL and 
MGL) were not detected in this study. In addition, no informa-
tion on expression levels of these enzymes in the epidermis was 
reported. Thus, these enzymes are not expected to play a major 
role in epidermal TAG catabolism.
The immanent role of epidermal TAG stores in acylce-
ramide synthesis is also evident from a mutant mouse model 
lacking the principal enzyme for epidermal TAG synthesis, 
acyl-CoA:diacylglycerol acyltransferase-2 (DGAT-2). DGAT-
2-deficient mice also exhibit drastically reduced epidermal acyl-
ceramide levels and increased transepidermal water loss due 
to a severe permeability barrier dysfunction of the skin.81 This 
phenotype is essentially identical to the one observed in CGI-
58-deficient mice and also leads to postnatal death within a few 
hours after birth. In contrast to CGI-58-deficient mice, however, 
the skin defect in DGAT-2-deficient mice seems to include a 
systemic component, because transplantation of full-thickness 
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of lysophosphatidic acid and increase the levels of phosphatidic 
acid, thereby also affecting PPAR activity. 9-cis retinoic acid, the 
lipid ligand for RXR activation, derives from retinyl ester stores 
in keratinocytes. Its generation requires retinyl ester hydrolysis 
and retinol oxidation in a two-step process. Notably, retinyl ester 
hydrolysis in human epidermis is mediated by PNPLA4 (also 
annotated as gene sequence 2, GS2), a protein with high struc-
tural homology to ATGL.98,99
Conclusion
Recent advances in the understanding of epidermal differentia-
tion and the formation of the skin permeability barrier acknowl-
edge the immanent role of TAG-derived FAs in these processes. 
Studies with mutant mouse models and patients with NLSDI 
demonstrated that FAs originating from the lipolytic hydroly-
sis are a prerequisite for the formation of acyl(glucosyl)cerami-
des, which are essential for the formation of a functional CLE. 
However, important questions concerning the role of neutral 
lipid metabolism and epidermal lipid remodeling remain unan-
swered. For example, it is unclear why FAs must derive from 
TAGs for acylceramide synthesis and which CGI-58-regulated 
lipase mediates the hydrolysis of TAGs in keratinocytes. Future 
studies are required to elucidate how various activities of CGI-
58 affect the formation of bioactive lipids that are involved in 
cellular signaling. These processes may include FA or phospha-
tidic acid activation of nuclear hormone receptors, which are 
known to control the complex and essential differentiation of 
keratinocytes during permeability barrier development.
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an enzyme activity has been described in the epidermis the   
corresponding gene and protein remain unidentified.89
The Role of CGI-58 in Keratinocyte Differentiation
Epidermal differentiation is a highly regulated, sequential process, 
which starts with the migration of keratinocytes from the prolif-
erating, basal cell layer of the epidermis through the spinous and 
granular layer and ends with the formation of the stratum cor-
neum.90,91 Using both quantitative real-time reverse transcription 
polymerase chain reaction and immunohistochemistry, Akiyama 
et al.67 demonstrated a crucial role of CGI-58 in keratinocyte 
differentiation by showing that epidermal CGI-58 transcription 
is massively upregulated during cornification and fetal develop-
ment of human skin. In accordance with these observations, a 
reduced expression of keratinization markers was observed in 
CGI-58 silenced keratinocytes (via siRNA) and murine CGI-
58-deficient epidermis.62,67 The mechanisms by which CGI-58 
affects these biological processes remain speculative but it is con-
ceivable that CGI-58 is involved in the generation of lipid ligands 
for nuclear hormone receptors that regulate keratinocyte differ-
entiation. Human epidermis expresses all isoforms of peroxisome 
proliferator-activated receptor (PPAR, isoforms: PPAR-alpha, 
PPAR-beta/delta, PPAR-gamma), retinoid X receptor (RXR, iso-
forms: RXR-alpha, RXR-beta, RXR-gamma), as well as liver X 
receptor (LXR, isoforms: LXR-alpha, LXR-beta).92-94 Activation 
of these receptors induces epidermal differentiation and improves 
permeability barrier homeostasis by stimulating epidermal lipid 
synthesis, lamellar body formation and secretion of lipids and 
enzymes, which are required for processing of extracellular lipids 
in the cornified layer that facilitate adequate lamellar membrane 
formation and consequently, normal permeability barrier func-
tion (Fig. 1).95
According to the current concept, PPARs and LXRs form 
heterodimers with RXRs. Ligand-binding causes the dissociation 
of co-repressors and the concurrent recruitment of co-activator 
proteins to the complex. This, in turn, promotes transcription 
of downstream target genes.96,97 Endogenous lipid-ligands for 
PPARs, LXRs, as well as RXRs include FAs, oxysterols and 
9-cis retinoic acid, respectively. CGI-58 may contribute to the 
generation of these lipids. For example, the activation of TAG 
hydrolysis by CGI-58 may provide FAs for PPAR activation. The 
LPAAT activity of CGI-58 may lower the cellular concentration 
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